Back to Journals » Clinical Ophthalmology » Volume 5

Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data

Authors Pickett A

Published 9 September 2011 Volume 2011:5 Pages 1287—1290

DOI https://doi.org/10.2147/OPTH.S24394


Picket, Andy
Toxin Science Limited, Wrexham, UK; Botulinum research Center, UMASS Dartmouth, MA, USA

Modern clinical use of botulinum toxin (BoNT) by doctors requires evidence- based facts and data to support their work. In particular, these need to be unbiased and complete. Too often in the past, speculative statements have been used and repeated until injectors have come to believe they are solid facts.1 Yet no supporting data exist. Consequently, doctors have often been reluctant to change to or even try other products because of what they have been told. This has not been a good situation for either clinicians or patients. We have published about these "urban legends"1 and tried, on many occasions, to correct these inaccuracies (see, for example,2,3).
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]